Tropoelastin-derived peptides reset VSMC epigenome to block osteochondrogenic shift and vascular calcification

Hypothesis Exogenous tropoelastin-derived peptides (TEPs) restore youthful elastin signaling in vascular smooth muscle cells (VSMCs), thereby inhibiting the phosphate‑driven osteochondrogenic transdifferentiation that underlies arterial stiffening and calcification.

Mechanistic Rationale Aging reduces tropoelastin synthesis, leading to elastin fragmentation that actively nucleates calcium phosphate crystals Aging-related elastin fragmentation actively promotes calcium phosphate crystal growth on fibers. Fragmented elastin also triggers VSMCs to adopt Runx2+/BMP2+ osteochondrogenic phenotypes under phosphate stress VSMCs transdifferentiate to osteochondrogenic phenotypes, expressing Runx2 and BMP2 under phosphate stress. This shift is amplified by a local phosphate‑pyrophosphate imbalance governed by tissue‑nonspecific alkaline phosphatase (TNAP) Imbalance in phosphate and pyrophosphate, regulated by tissue-nonspecific alkaline phosphatase (TNAP), directly controls VSMC calcification.

We propose that TEPs act as matricryptic cues that reactivate elastin‑receptor complexes (e.g., integrin αvβ3, lysyl oxidase) and downstream elastin‑induced signaling pathways (FAK‑Src‑ERK). Reactivation of these pathways restores a contractile VSMC epigenome by:

1. Increasing histone H3K27ac at smooth‑muscle contractile gene promoters (e.g., ACTA2, MYH11).
2. Reducing H3K4me3 enrichment at osteogenic loci (RUNX2, SP7).
3. Lowering intracellular calcium‑phosphate microdomains via enhanced annexin‑A2 mediated phosphate efflux, thereby decreasing the substrate for hydroxyapatite nucleation.

Consequently, TEPs uncouple phosphate sensing from osteogenic transcription, shifting the VSMC phenotype back toward a quiescent, contractile state even in the presence of elevated extracellular phosphate.

Predictions & Experimental Design

1. In vitro: Human aortic VSMCs cultured in osteogenic medium (high β‑glycerophosphate, ascorbic acid) will show decreased Runx2 expression and alkaline phosphatase activity when treated with physiologically relevant concentrations of TEPs (1‑10 µg/mL) compared with scrambled peptide controls. Measurements: qPCR for RUNX2, BMP2; Alizarin Red staining; western blot for phospho‑FAK and phospho‑ERK.
2. Ex vivo: Human aortic rings from older donors (≥65 yr) will exhibit reduced calcium deposition (von Kossa) after 14‑day perfusion with TEPs in a pulsatile flow bioreactor, alongside increased elastin content (Verhoeff‑Van Gieson) and contractile response to phenylephrine.
3. In vivo: ApoE‑/‑ mice fed a high‑phosphate diet will receive weekly intraperitoneal injections of TEPs or control peptide for 12 weeks. Endpoints: pulse wave velocity (PWV), aortic calcification burden (micro‑CT), VSMC phenotype (immunofluorescence for α‑SMA vs. Runx2), and elastin integrity (elastic staining).
4. Mechanistic readouts: ChIP‑seq for H3K27ac and H3K4me3 in isolated VSMCs to confirm epigenetic reprogramming; intracellular calcium‑phosphate quantification using Fos‑linked calcium sensors.

Potential Outcomes & Falsifiability

• If TEPs significantly reduce calcification, improve PWV, and restore a contractile VSMC epigenome compared with controls, the hypothesis is supported.
• If TEPs fail to alter VSMC phenotype, calcification, or arterial stiffness despite adequate tissue delivery, the hypothesis is falsified, indicating that elastin-derived signaling is insufficient to override phosphate‑driven osteogenic programming.

Implications Confirming this mechanism would reposition elastin not as a passive structural scaffold but as an active regulator of VSMC fate, suggesting that peptide‑based elastin mimetics could reverse or prevent age‑related arterial stiffening—a therapeutic avenue testable in existing cohorts such as the BiKE study Ulf Hedin's Vascular Surgery group uses the BiKE cohort and amenable to evaluation with scRNA‑seq platforms Ulf Eriksson and Lars Jakobsson's groups study VEGF‑B/PDGF signaling.

Key open question: Whether systemic TEP administration can achieve sufficient vascular elastin receptor engagement without off‑target effects on other tissues remains to be determined.